Everyone with ovarian cancer deserves genetic testing.


Why Age 70+ Shouldn't Rule Out Genetic Testing

Study Reference: Gynecologic Oncology | Retrospective Registry Study 

The Bottom Line

Ovarian cancer is predominantly a disease of older adults, yet women aged 70 and older are far less likely to receive germline genetic testing. This study of over 113,000 patients reveals that 6.6% of patients aged 70+ carry actionable, high-risk genetic mutations. Older women were 1.5 times less likely to report a family history of cancer. Relying on family history to decide who gets genetic testing in this age group leaves a significant number of mutation carriers unidentified, missing crucial opportunities for targeted therapies and family screening.

Key Findings at a Glance

  • Significant Mutation Rate: While overall variant rates decrease with age, nearly 1 in 15 women aged 70+ with ovarian cancer still carries an actionable germline mutation.

  • Family History Unreliable: Older patients are significantly less likely to have a documented family history of cancer. A negative family history in a 75-year-old is not a reliable indicator of low genetic risk.

  • Shift in Gene Profiles: While BRCA1 mutations dominate in younger women, BRCA2 is more prevalent with age. Additionally, Lynch syndrome is a much less likely cause in this age group, and other high-risk genes beyond BRCA (BRIP1, PALB2) play a larger relative role.

What This Means for Ovarian Cancer Support Nurses

Clinical AreaPractical Action for Support Lines
Addressing Age AssumptionsReassure callers in their 70s and 80s that genetic testing remains valuable regardless of age—both for personalised treatment choices (e.g., PARP inhibitors) and for their relatives.
Don't rely on family historyRemind nurses and callers that missing or small family trees in older generations make "family history" a poor gatekeeper for testing.
Genetic Testing for FamiliesHighlight that identifying a mutation in a 75-year-old patient provides vital risk-reduction options for her children and grandchildren, with a focus on BRCA2 and other ovarian high-risk genes.

Quick Tags:

#GeneticTesting #GeriatricOncology #BRCA2 #LynchSyndrome #PARPInhibitors #CascadeTesting #SupportNursing #OvarianCancer

Comments

Post a Comment

Popular posts from this blog

An impossible dream?

Image
Reducing ovarian cancer mortality through screening: an impossible dream? https://tinyurl.com/4524jh8f The history of screening tests for ovarian cancer is not good. Two huge trials; the UKCTOCS with  more than 200,000 recruits over 20 years and the PLCO trial with more than 3 million pathology samples  sho wed no benefit in terms of survival from ovarian cancer. This article addresses the stages of ovarian cancer using  an alternative approach called the clinical continuum,  which divides cancer into 3 phases ,  no disease, pre-clinical  (detectable disease) , and  clinical (overt cancer). Obviously for a screening test to be effective ,   cancer needs to be detected before the clinical  phase. However, ovarian cancer is unlike other cancer in that the precursor occurs in the fallopian tube and the re is an argument to say that ,  by the time ovarian cancer has occurred ,  it is always advanced and metastatic .   T his time in...
Read more

Sugar doesn’t feed cancer

Image
Revisiting the Warburg-Based “Sugar Feeds Cancer” Hypothesis: A Critical Appraisal of Epidemiological, Experimental and Mechanistic Evidence https://tinyurl.com/3v2tysdt Many clinical care professionals receive queries from cancer patients about whether they should modify their diet to red u ce consumed sugar. This concern is based on a misunde r standing of some basic medical research known as the Warbur g effect. Research from 1956 show ed that cancer cells alter their metaboli sm to enable increased glucose uptake and increase energy production. A misunderstanding of this effect has led to incorrect dietary advice to cancer patients suggesting sugar restriction may be benefi cial. As a result, malnutrition , which is already a s i gnificant cause of morbidity for cancer patients , can be exacerbated . No hard evidence that low sugar diets alter survival exists. Some anecdotal reports suggest a slight correlation with risk. This study is a n appraisal of all credible re...
Read more

Natural selection causing drug resistance

Image
Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA https://tinyurl.com/2xtv64nx Drug resistance is the major cause of death from ovarian cancer. Why this occurs is problematic and varies with individuals. This s tudy looks at the evolving genetic mutations which cause previously effective chemo to lose its ability to control the cancer. Using new sequence genetic profiling of circulating tumour DNA , this prospective study followed the course of disease for 18 women with ovarian cancer from diagnosis to recurrence. The main finding was that the genetic clone s which disabled the chemo response w ere present at diagnosis for all these women . This suggests that evolutional preselection is occurring , whereby the environment of chemo promotes the increase in effectiveness of harmful genetic clone s . The authors suggest that understanding this evolutionary effect should lead to a  change in management, alter the environment, and prevent the...
Read more